Ipsen extends deadline for Medicis deal
French company Ipsen says that it has decided, jointly with USA-based Medicis, to extend to July 15 the deadline for entering into an agreement relating to the exclusive distribution and development rights of its botulinum toxin A product for the esthetic market in Europe and subsequently in other territories. This deadline was initially set for 15 April 2006.
As previously announced on March 20, Ipsen and Medicis entered into an agreement granting the latter rights to develop, distribute and commercialize Ipsen's product in the USA, Canada and Japan for esthetic use by physicians. The product is commonly referred to as Reloxin in the US esthetic market and Dysport for medical and esthetic markets outside the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze